Skip to main content
Glama

Storting No

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, openWorldHint, idempotentHint, and destructiveHint:false, and the description adds substantial behavioral context: graceful degradation when GLEIF/OpenFIGI is unavailable, ambiguous matches return figi_candidates, unresolved identifiers are explicitly listed, identifiers are source-labelled, and internal cascading through multiple endpoints is disclosed. This is exactly the kind of value that annotations alone do not provide.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and dense, but every clause earns its place: example queries are front-loaded, the use-first guidance is immediate, and the supported-type details are organized. Some redundancy exists (e.g., 'Use FIRST' being implied by later phrasing), and the sheer volume of caveats could be trimmed, but overall it is structured for an agent to find the key facts quickly.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the full burden of explaining return behavior, and it does so well: ambiguous company matches return figi_candidates, unresolved identifiers are surfaced under unresolved, drug lookups return RxCUI/ingredient/brand/citation, and degradation behavior is stated. For a tool of this complexity, nothing critical is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so baseline is 3, but the description adds crucial parameter meaning beyond the schema: the value must be the entity name only, not the full noun phrase; bond issuers must be passed exactly as printed; accepted input forms include ticker, CIK, ISIN, and name for company; and drugs accept brand or generic name. These details materially affect correct invocation.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description uses a specific verb-and-resource pairing: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It also distinguishes itself by positioning the tool as the first step before other tools that need IDs, and it enumerates supported types (company, drug) with concrete examples. This makes it easy to separate from siblings like entity_profile or compare_entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly instructs 'Use FIRST whenever you have a name but need an ID,' which is a clear when-to-use signal. It does not, however, name sibling tools or provide explicit when-not-to-use guidance against entity_profile, compare_entities, or search_within, so it stops short of a full 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Storting No toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation2/5

Several tools are near-duplicates: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded all route questions to the same underlying toolset with only minor differences. Additionally, the five polymarket_* tools overlap significantly in purpose, and the mix of Storting parliament tools with a general-purpose data platform creates confusion about which tool is appropriate.

Naming Consistency2/5

Tool names use snake_case but with inconsistent conventions. Some are verb-first (get_, list_, discover_, validate_), while others are noun-first (entity_profile, bet_research, recent_alerts). There are predictable prefixes like ask_pipeworx and polymarket_, but overall the naming pattern is not uniform, making it harder to predict tool names.

Tool Count2/5

With 38 tools, the count exceeds the 25-tool threshold for 'too many.' Many tools are unrelated to the server name 'Storting No' (which implies a Norwegian parliament focus), and the broad range of data-research and prediction-market tools feels bloated for the apparent scope. A smaller, more focused set would improve coherence.

Completeness3/5

The Storting-related tools cover the main parliamentary entities (cases, parties, representatives, sessions, votes) and include an export fallback for any additional data.stortinget.no resource. The Pipeworx side has meta-tools (ask, discover, suggest) and specialized analyses (entity_profile, validate_claim, polymarket_*). However, there are notable gaps, such as no direct tool for searching parliamentary speeches or committee documents without relying on the generic export, and the mixed domains leave some workflows incomplete.

Resources